 |
|
|
|
 |
|
|
| Article 1 to 10 out of 15 concerning Gilead Sciences, Inc.
|
-
Second Phase III Study Evaluating Gilead's Viread(R) for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
(27 Jun 2007)
Gilead Sciences, Inc. announced that Study 103, a Phase III clinical trial evaluating the company's once-daily anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovir DF) 300 mg as a potential treatment for chronic hepatitis B virus ...
-
Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
(05 Mar 2007)
Gilead Sciences, Inc. announced 24-week data from a Phase II clinical trial evaluating three doses of GS 9137 (elvitegravir), a novel oral HIV integrase inhibitor. According to the company, the data show statistically superior reductions in viral ...
-
Gilead completes Phase II Clinical Trial of Novel Investigational HIV Integrase Inhibitor GS 9137
(27 Feb 2007)
Study Meets Primary Endpoint of Non-inferiority
Gilead Sciences, Inc. announced the completion of a Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor. The clinical study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving ...
-
Gilead and Achillion discontinue development of treatment for hepatitis C viral infection
(12 Feb 2007)
Gilead Sciences and Achillion Pharmaceuticals announced their decision to discontinue the development of GS 9132, also known as ACH-806, for the treatment of hepatitis C viral (HCV) infection, based upon preliminary data from a Phase 1b/2 trial. ...
-
Carla A. Hills Joins Gilead Sciences' Board of Directors
(25 Jan 2007)
Gilead Sciences, Inc. announced that Carla A. Hills has been appointed to the company's Board of Directors, bringing the number of Directors to 10.Mrs. Hills is the chair and chief executive officer of Hills & Company, International Consultants, a ...
-
Gilead Announces Generic Viriad Licensing Agreements with Eight India-Based Companies
(26 Sep 2006)
Gilead Sciences, Inc. announced that the company has signed eight new non-exclusive license agreements with generic companies in India. These licensing agreements grant to Alkem Laboratories Ltd., Aurobindo Pharma Ltd., FDC Ltd., J.B. Chemicals & ...
-
Gilead licenses Manufacturing and Distribution of Generic Versions of Viread to India-Based Companies
(16 Aug 2006)
Gilead Sciences, Inc. announced that the company has signed non-exclusive license agreements to provide generic versions of tenofovir disoproxil fumarate (sold by Gilead under the brand name Viread(R)) to three generic manufacturers in India. These ...
-
Gilead Sciences Exercises Option to Acquire Corus Pharma for $365 Million
(04 Aug 2006)
Gilead Sciences, Inc. announced that the company has exercised its option to purchase privately-held Corus Pharma for $365 million. The transaction is expected to close in the third quarter, subject to clearance under the Hart-Scott-Rodino Antitrust ...
-
Gilead Sciences Agrees to Exercise Its Option to Acquire Corus Pharma for $365 Million
(21 Jul 2006)
Gilead Sciences, Inc. has agreed to exercise its option to purchase Corus Pharma for $365 million. Gilead expects formal exercise of this option to be enacted within 10 business days, and anticipates that the deal would close in the third quarter of ...
-
Diatos Announces Acquisition of Specialty Cancer Product DaunoXome from Gilead Sciences
(15 May 2006)
Diatos SA announced an exclusive licensing agreement with Gilead Sciences, Inc. on the worldwide development and commercialization rights to DaunoXome. DaunoXome is a marketed liposomal formulation of daunorubicin, which has been approved for ...
Additional information
Gilead Sciences, Inc.
Foster City, CA, United States of America
Company
|
|
|
|
|
|
Top
